Given the availability of both ERα clinical-grade antibodies and ERα-targeted drugs, repurposing of SERMs and anti-estrogens could rapidly be tested in prospective clinical studies in combination with anti-androgens in patients with PCa and a progressive disease. Here, ESR1 is linked to posterior cortical atrophy.